A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
NCT04705090
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
PTCL
Interventions
DRUG:
YY-20394 treatment
Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.